MI Arrowhead Publishers and Conferences
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Molecular Interventions 5:30-41, (2005)
© American Society for Pharmacology and Experimental Therapeutics
10.1124/mi.5.1.7
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Traynor, J. R.
Right arrow Articles by Neubig, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Traynor, J. R.
Right arrow Articles by Neubig, R. R.
Review

REGULATORs OF G PROTEIN SIGNALING & DRUGS OF ABUSE

John R. Traynor1 and Richard R. Neubig1,2

1 Departments of Pharmacology and 2 Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109


{titleArt_Traynor}

Drugs of abuse such as opioids and stimulants share a common dopaminergic reward pathway; however, in response to continual intermittent exposure to such drugs, there are neuronal alterations leading to changes in behavior. Regulators of G protein signaling (RGS) are proteins that negatively regulate G protein signaling and are expressed in brain areas important for the pharmacology of abused drugs. Moreover, the level of expression of several of these proteins is regulated by abused drugs. In this article, we discuss RGS proteins, their regulation by morphine and stimulants, and how altered levels of these proteins affect cell signaling to contribute to the pharmacology and behavioral consequence of abused drugs. Finally, we consider if RGS proteins represent viable targets for drug abuse medications.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
Q. Wang, L.-Y. Liu-Chen, and J. R. Traynor
Differential Modulation of {micro}- and {delta}-Opioid Receptor Agonists by Endogenous RGS4 Protein in SH-SY5Y Cells
J. Biol. Chem., July 3, 2009; 284(27): 18357 - 18367.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
D. L. Roman, S. Ota, and R. R. Neubig
Polyplexed Flow Cytometry Protein Interaction Assay: A Novel High-Throughput Screening Paradigm for RGS Protein Inhibitors
J Biomol Screen, July 1, 2009; 14(6): 610 - 619.
[Abstract] [PDF]

Home page
 Mol. Pharmacol.Home page
M. J. Clark, J. J. Linderman, and J. R. Traynor
Endogenous Regulators of G Protein Signaling Differentially Modulate Full and Partial {micro}-Opioid Agonists at Adenylyl Cyclase as Predicted by a Collision Coupling Model
Mol. Pharmacol., May 1, 2008; 73(5): 1538 - 1548.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. L. Roman, J. N. Talbot, R. A. Roof, R. K. Sunahara, J. R. Traynor, and R. R. Neubig
Identification of Small-Molecule Inhibitors of RGS4 Using a High-Throughput Flow Cytometry Protein Interaction Assay
Mol. Pharmacol., January 1, 2007; 71(1): 169 - 175.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.